Replimune Group (REPL) AI Stock Analysis

• Market Cap: $742.42M
• Dividend Yield: N/A
• Average Volume (3M): 924.23K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.61
• Revenue Growth: N/A
• EPS Growth: 4.28%
• Country: US
• Employees: 331
• Sector: Healthcare
• Sector Strength: 74
• Industry: Biotechnology
• EPS (TTM): -3.14
• Shares Outstanding: 77,014,780
• 10 Day Avg. Volume: 868,187
• 30 Day Avg. Volume: 924,230
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.68
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -190.28
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $22.14
• Price Target Upside: 129.67% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7

Replimune Group's stock score reflects its early-stage status in the biotechnology sector, characterized by significant R&D investments leading to negative earnings and cash flows. While the company shows strong equity, the current technical indicators suggest mixed to bearish market momentum. Valuation remains challenging due to negative earnings. The company's future success hinges on the development and commercialization of its products.

Positive Factors

Clinical Development

RP1 is likely to be a successful first therapeutic in Replimune's skin cancer franchise, given IGNYTE data in melanoma.

Financial Stability

Replimune's improved cash balance further solidifies the company's position heading into the potential launch of RP1.

Regulatory Progress

The FDA granted breakthrough therapy designation for RP1 + nivolumab in anti-PD-1-failed melanoma.

Negative Factors

Adverse Events

The combination of RP1 + Opdivo demonstrated a relatively benign safety profile, with 12.8% of patients experiencing G3+ treatment-related adverse events.

Market Competition

RP1 + Opdivo's response rate was consistent across all sub-groups, but competition remains due to other treatments like Amtagvi™.

Regulatory Risks

The FDA's decision not to hold an Advisory Committee meeting could imply potential uncertainties in the review process.

Replimune Group Business Overview & Revenue Model

Company Description

Replimune Group, Inc. (REPL) is a biotechnology company focused on developing oncolytic immunotherapies for the treatment of cancer. The company operates in the healthcare sector, specifically within the biopharmaceutical industry. Replimune's core products are based on its proprietary Immulytic platform, which is designed to enhance the systemic anti-tumor immune response by using genetically engineered viruses to selectively infect and kill cancer cells while sparing normal tissue.

How the Company Makes Money

Replimune Group generates revenue primarily through partnerships, collaborations, and licensing agreements with other pharmaceutical and biotechnology companies. These partnerships often involve upfront payments, milestone payments, and potential royalties based on the successful development and commercialization of their oncolytic immunotherapies. While Replimune is still in the clinical trial phase for many of its product candidates, such collaborations are crucial for funding ongoing research and development activities. Additionally, the company may also receive government grants or funding from cancer research organizations to support its innovative work in oncolytic virotherapy.

Replimune Group Financial Statement Overview

Summary

Replimune Group is in an early growth stage, heavily investing in R&D, which impacts profitability and cash flow. While the company maintains a strong equity position, it experiences significant operational losses typical for its industry phase. Future financial performance will depend on successful product development and commercialization.

Income Statement

Replimune Group has shown minimal revenue with a TTM revenue of $4.04 million, indicating an initial phase of commercial operations. The company is experiencing significant negative EBIT and EBITDA margins due to high operating expenses, typical for biotechnology firms in research phases. Net profit margins are also deeply negative, reflecting ongoing losses as the company invests heavily in R&D.

Balance Sheet

The balance sheet shows a strong equity position relative to liabilities, with a debt-to-equity ratio of 0.06 in TTM. The equity ratio stands at 79.9%, indicating a low leverage. However, substantial net losses contribute to a low return on equity, typical for companies heavily investing in development before achieving commercial success.

Cash Flow

Operating cash flow remains negative, reflecting cash outflows associated with R&D activities. Despite this, the company has managed robust financing activities, maintaining liquidity with significant cash reserves. Free cash flow has shown a marginal decline, emphasizing the need for efficient cash management to support ongoing operations.

Breakdown
Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
-2.65M	-2.45M	-4.58M	-4.14M	-1.81M
	EBIT
-234.77M	-177.08M	-118.31M	-79.95M	-56.20M
	EBITDA
-230.20M	-170.30M	-114.41M	-76.48M	-52.60M
	Net Income Common Stockholders
-215.79M	-174.28M	-118.04M	-80.87M	-52.63M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
420.67M	583.39M	395.65M	476.30M	168.56M
	Total Assets
487.72M	646.59M	461.19M	543.10M	234.10M
	Total Debt
75.87M	60.76M	32.84M	33.28M	41.79M
	Net Debt
1.41M	-85.83M	-73.11M	-149.24M	-17.71M
	Total Liabilities
113.21M	91.30M	49.96M	44.37M	50.38M
	Stockholders Equity
374.51M	555.29M	411.23M	498.73M	183.72M
Cash Flow		Free Cash Flow
-191.13M	-130.32M	-84.52M	-63.78M	-67.09M
	Operating Cash Flow
-185.47M	-128.05M	-82.18M	-61.39M	-60.55M
	Investing Cash Flow
97.20M	-142.50M	-1.81M	-188.78M	-5.23M
	Financing Cash Flow
16.28M	311.30M	6.60M	372.46M	100.17M

Replimune Group Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 9.64
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For REPL, the sentiment is Negative. The current price of 9.64 is above the 20-day moving average (MA) of 8.19, below the 50-day MA of 10.36, and below the 200-day MA of 11.31, indicating a neutral trend. The MACD of -0.20 indicates Negative momentum. The RSI at 58.80 is Neutral, neither overbought nor oversold. The STOCH value of 95.19 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for REPL.

Replimune Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.28B	3.75	-42.72%	2.86%	17.70%	2.03%
REPL	42 Neutral	$742.42M	―	-50.50%	―	―	4.28%
PRAX	42 Neutral	$758.94M	―	-70.98%	―	249.53%	56.59%
XNCR	41 Neutral	$772.71M	―	-34.74%	―	-36.72%	-64.37%
RCKT	40 Underperform	$813.58M	―	-54.14%	―	―	6.99%
NTLA	39 Underperform	$894.39M	―	-54.00%	―	59.55%	3.09%

Replimune Group Corporate Events

Replimune Group Advances Cancer Treatment with FDA Submission

Replimune Group, Inc. has made significant strides in cancer treatment with its submission of a biologics license application to the FDA for its lead product, RP1, in combination with nivolumab, targeting advanced melanoma. The FDA has granted Breakthrough Therapy designation to this innovative therapy, which could expedite its availability for patients with limited options. This development marks a promising advancement for Replimune, as their novel oncolytic immunotherapy shows potential for substantial improvement over existing treatments.